ABBOTT LABORATORIES TO ACQUIRE MEDISENSE, INC.
ABBOTT PARK, Ill., and WALTHAM, Mass., March 29 /PRNewswire/ -- Abbott Laboratories (NYSE NYSE
See: New York Stock Exchange : ABT) and MediSense, Inc. (Nasdaq: MSNS MSNS Michigan State Numismatic Society
MSNS Medical Society of Nova Scotia
MSNS Master of Science in Network Security
MSNS Muftisays Net Station (forum) ) today announced that they have signed a definitive agreement through which Abbott will acquire MediSense, the biosensor A device that detects and analyzes body movement, temperature or fluids and turns it into an electronic signal. See lab on a chip and data glove.
Biosensor technology leader in blood glucose self-testing systems for people with diabetes.
Under the terms of the agreement, Abbott will make a tender offer to acquire 100 percent of the outstanding shares of MediSense for $45 per share, or an equity value of approximately $876 million. The Abbott and MediSense boards of directors have endorsed the offer. The tender offer is expected to be completed in approximately five weeks, subject to regulatory approvals and customary closing conditions. Following the tender offer, MediSense will be merged into a wholly owned subsidiary Wholly Owned Subsidiary
A subsidiary whose parent company owns 100% of its common stock.
In other words, the parent company owns the company outright and there are no minority owners. of Abbott Laboratories, and each remaining MediSense shareholder will receive $45 per share in exchange for each MediSense share held.
"We are extremely pleased to add MediSense's superior technology and outstanding people to our company," said Duane L. Burnham, chairman and chief executive officer of Abbott Laboratories. "MediSense fits very well with our diagnostics operations, and will create many opportunities for synergy with our other divisions as well."
According to Miles D.White, senior vice president, diagnostics operations, the acquisition advances Abbott's interests in the glucose monitoring market. "This important strategic step, combined with other internal and external initiatives to secure industry-leading technology in glucose monitoring, will position Abbott very favorably in this market. In addition to providing immediate access to the fastest-growing segment of the diagnostics market, MediSense's research and development program will augment our existing work to develop and commercialize future non-invasive monitoring technologies," said White.
"We are delighted to become a part of the world's leading diagnostics company,'' said Robert L. Coleman, Ph.D., president and chief executive officer of MediSense. ``The combination of the two organizations will accelerate market growth and will ensure continued development and availability of therapies to improve the care of people with diabetes."
MediSense manufactures products that allow people with diabetes to routinely measure blood glucose which is critical to diabetes management. The products are compact, easy-to-use home glucose meters and disposable single-use test strips. MediSense was the first company to develop a biosensor-based blood glucose self-testing system. MediSense's leading system, the Precision Q.I.D., provides accurate results, with less blood, faster than any competing product.
The MediSense subsidiary of Abbott will continue to be located in Massachusetts, with Dr. Coleman remaining as president of the subsidiary. MediSense is a worldwide developer, manufacturer and marketer of blood glucose self-testing systems that enable people with diabetes to manage their disease more effectively. MediSense believes the convenience and simplicity of its products promote increased testing compliance by individuals with diabetes and provide for more effective management of their condition.
Abbott Laboratories is a diversified global manufacturer of health care products, employing 50,000 people. The company researches, develops and markets pharmaceutical, diagnostic, nutritional and hospital products. In 1995, the company's sales and net earnings were $10.0 billion and $1.7 billion, respectively, with earnings per share of $2.12.
/CONTACT: Media: Rick Moser, 847-937-8943, or Financial Community: Cathy Babington, 847-937-3931, both of Abbott Laboratories; or Media & Financial: John Chiricotti of MediSense, 617-895-6007/
/This release, along with past Abbott Laboratories releases, is available by fax at no charge by calling Company News On Call at 1-800-758-5804 and entering the code 110328./
CO: Abbott Laboratories; MediSense, Inc. ST: Illinois, Massachusetts IN: MTC mtc - A Modula-2 to C translator.
ftp://rusmv1.rus.uni-stuttgart.de/soft/Unixtools/compilerbau/mtc.tar.Z. SU: TNM TNM tumor-nodes-metastasis; see under staging.
tumor, nodes and metastases; a system of cancer staging (see TNM staging).
AS -- NYF031 -- 3527 03/29/96 10:07 EST EST electroshock therapy.